AQUEDUCT
DEAD

Serial Number

98220959

Owner

Atropos Health, Inc.

Attorney

THOMAS Y. YEE

Filing Date

Oct 12, 2023

Add to watchlist:

No watchlists yet
View on USPTO

AQUEDUCT Trademark

Serial Number: 98220959

AQUEDUCT is a trademark filed by Atropos Health, Inc. on October 12, 2023. The trademark is classified under Class 38 (Telecommunications), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Atropos Health, Inc. (20 trademarks)

169 Madison Avenue, Unit 2242
New York, NY 10016

Entity Type: 03

Trademark Details

Filing Date

October 12, 2023

Registration Date

Not Registered

Published for Opposition

February 10, 2026

Goods & Services

Business consulting and data management in the field of clinical trials, namely, providing information management services by means of data compilation; collection, reporting, managing, structuring, activating, and analysis of healthcare records, clinical records, and life science report and article-related data for business purposes; services consisting of the registration, collection, transcription, compilation, clarification, enablement, enhancement, management, mapping, structuring, activating, and systemization of written communications and data; all of the foregoing services provided to healthcare providers and researchers for medical diagnosis and treatment purposes and not for medical and health care education and may also be provided by means of artificial intelligence

Providing medical information to healthcare providers and healthcare professionals, and life sciences companies to help them make informed decisions for patient diagnosis and treatment and clinical trial design, emulation, strategy, and prioritization; providing health data analysis to healthcare providers and healthcare professionals in the medical and patient-care industry to help them to assess clinical data for the purpose of patient diagnosis and treatment and improving quality of care in the medical and healthcare industry; providing information and data related to patient data, namely, demographics, diagnoses, procedures, medications, laboratory values, clinical notes, mortality, and length of stay information for patients to inform clinical care decisions and research and to inform life science company corporate strategy, research and development, and marketing and brand planning; providing on-line medical and clinical record and life science articles and reports analysis services designed to provide healthcare providers and healthcare professionals with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; providing on-line medical and clinical record and life science articles and reports analysis services designed to provide medical providers with custom tailored information about the outcomes for patients with similar symptoms and evidence needed for patient care decisions; compiling, clarifying, enabling, enhancing, managing, mapping, and analyzing medical and clinical data and life science articles and reports for medical treatment purposes; all of the foregoing services provided to healthcare providers and researchers for medical diagnosis and treatment purposes and not for medical and health care education and may also be provided by means of artificial intelligence

Providing medical, health, and scientific research information, research data, and research services to assist healthcare providers, healthcare professionals, and life sciences companies in making informed decisions for patient diagnosis and treatment and clinical trial design, emulation, strategy, and prioritization; medical research services, namely, collecting, storing, indexing, analyzing, updating, managing, sharing, and reporting real world data to create actionable insights for use by healthcare providers, healthcare professionals, and life sciences companies; providing medical and scientific research information in the field of clinical trials and life sciences; compiling data for research purposes in the field of medical science and medical consultancy and life sciences; software as a service (SAAS) services featuring software for providing diagnosis and treatments recommendations for physicians and researchers; software as a service (SAAS) services featuring software for collecting, storing, indexing, analyzing, updating, managing, sharing, clarifying, enabling, enhancing, managing, mapping, structuring, activating, and reporting clinical trial, data, electronic health records, claims data, life science articles and report, and medical research data to evaluate and recommend medical diagnoses and treatments; software as a service (SAAS) services featuring software for searching, organizing and managing data, namely, demographics, diagnoses, procedures, medications, laboratory values, clinical notes, mortality, and length of stay information for patients to inform clinical care decisions and research; software as a service (SAAS) services featuring software for providing healthcare providers and healthcare professionals with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; software as a service (SAAS) services featuring software for compiling, clarifying, enabling, enhancing, managing, mapping, structuring, activating, and analyzing medical records and health data and life science articles and reports; software as a service (SAAS) services featuring software using a natural language or large language model, artificial intelligence, and machine learning for compiling, clarifying, enabling, enhancing, managing, mapping, structuring, activating, and analyzing medical records and health data and life science articles and reports; software as a service (SAAS) services featuring chatbot software using a natural language or large language model or artificial intelligence for compiling, clarifying, enabling, enhancing, managing, mapping, and analyzing medical records and health data and life science articles and reports and providing tailored reports regarding the data to physicians and researchers; compiling data for research purposes in the field of medical science and medical consultancy; software as a service (SAAS) services featuring software for data management, structuring and activation; all of the foregoing services provided to healthcare providers and researchers for medical diagnosis and treatment purposes and not for medical and health care education

Providing access to an electronic exchange of health data and data analyses across an integrated nationwide clinical research network; transmission of health and medical record and life science report and article database information and analyses of health and medical record and life science report and articles database information via telecommunications networks; electronic exchange of health data and life science report and articles insights via telecommunication networks for analyses, managing, structuring, activating, of health data from clinicians, health systems, academic medical centers, life sciences companies, and others; electronic transmission of health data; all of the foregoing services provided to healthcare providers and researchers for medical diagnosis and treatment purposes and not for medical and health care education and may also be provided by means of artificial intelligence

Filing History

EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jun 10, 2026 ETOP
ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Apr 16, 2026 MAB5
ABANDONMENT - AFTER PUBLICATION
Apr 16, 2026 ABN5
TEAS EXPRESS ABANDONMENT RECEIVED
Apr 15, 2026 EXAR
EXTENSION OF TIME TO OPPOSE RECEIVED
Mar 11, 2026 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Feb 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 4, 2026 NONP
EXPARTE APPEAL TERMINATED
Jan 16, 2026 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 16, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 16, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 16, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 16, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 16, 2026 CNEA
EX PARTE APPEAL-INSTITUTED
Jul 12, 2025 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Jul 12, 2025 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Jul 12, 2025 EXAF
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 11, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 11, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 11, 2025 ERFR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 9, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 9, 2025 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 13, 2025 GNFN
FINAL REFUSAL E-MAILED
Jan 13, 2025 GNFR
FINAL REFUSAL WRITTEN
Jan 13, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 25, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 25, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 25, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 11, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jun 11, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jun 11, 2024 CNRT
ASSIGNED TO EXAMINER
May 30, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 16, 2023 NWOS
NEW APPLICATION ENTERED
Oct 16, 2023 NWAP